Back to User profile » Dr Riju Ray
Papers published by Dr Riju Ray:
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1149-1161
Published Date: 22 April 2021
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
Moretz C, Hahn B, White J, Goolsby Hunter A, Essoi B, Elliott C, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2715-2725
Published Date: 29 October 2020
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
Moretz C, Bengtson LGS, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2047-2060
Published Date: 4 September 2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
Moretz C, Sharpsten L, Bengtson LGS, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1721-1737
Published Date: 1 August 2019